What CathRx does

CathRx Ltd is an Australian privately-held medical device company headquartered in Rydalmere, Sydney, that develops and manufactures electrophysiology (EP) catheters for the diagnosis and treatment of cardiac arrhythmias, principally atrial fibrillation. The company's product platform is built on a modular catheter architecture spanning catheter tubes, steering stylets, control handles, and full catheter assemblies, with the Khelix diagnostic catheter system supporting over 300 configuration combinations across fixed, steerable, and loop variants. The ElectroPulse Pulsed Field Ablation (PFA) System extends the platform into therapeutic ablation using 8F catheters, a 2800V generator, real-time tissue contact sensing, and a dual-use design that combines mapping and ablation in a single catheter.

CathRx monetises through direct enterprise field sales of the Khelix diagnostic system to hospitals and electrophysiology labs across seven approved regulatory markets (Australia TGA, New Zealand MedSafe, Europe CE Mark, USA FDA 510K, Korea MFDS, Taiwan TFDA, Thailand Thai FDA), with commercial sales commencing in 2024 from a low-volume Rydalmere pilot facility and high-volume production scheduled to scale at contract manufacturer New Deantronics in Chiayi, Taiwan from Q4 2025. The ElectroPulse PFA System is currently investigational and undergoing multi-centre pivotal clinical trials (FIH results reported November 2025, pivotal trial commenced December 2025) with future commercialisation contingent on regulatory approval. The company operates under ISO 13485:2016, MDSAP, and EC-Full Quality Assurance System certifications and holds an extensive granted patent portfolio across the USA, Europe, Japan, China, Germany, and Australia.

Customer segments are electrophysiologists and cardiac care hospitals performing arrhythmia diagnosis and atrial fibrillation ablation. CathRx's go-to-market is a direct enterprise sales motion supported by ISO-compliant manufacturing, regulatory affairs infrastructure, and senior commercial leadership with prior experience at Boston Scientific, Biosense Webster (J&J), Acutus, Biotronik, and Galaxy Medical. Revenue is not publicly disclosed; the company's funding to date includes an MTPConnect Medical Research Future Fund grant (AUD 711,590 lead tranche, June 2025) as part of broader Australian government medtech backing.

Name

CathRx

Legal name

CathRx Ltd

Website

https://cathrx.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

CathRx is a Sydney-based medical device company developing and commercialising modular electrophysiology catheters, including the Khelix diagnostic system and the investigational ElectroPulse pulsed-field ablation system, sold directly to hospitals and EP labs globally for atrial fibrillation diagnosis and treatment.

Ownership category

akta.pro rank

Product category

Electrophysiology Catheters

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Electrophysiology Mapping & Ablation Systems (HLAHAFAD)

akta.pro secondary industry

Electrophysiology (Heart Rhythm) (HLAKABAC)

Keywords

• Electrophysiology catheters
• Cardiac ablation devices
• Pulsed field ablation systems
• Atrial fibrillation treatment
• Cardiac mapping catheters

Headquarters

HQ city

Rydalmere

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Khelix Diagnostic Catheters Sales: Commercial sales of the Khelix diagnostic catheter system, including loop, steerable, and fixed EP catheters. Sales commenced in 2024 from the pilot manufacturing facility in Sydney, Australia. Larger-scale production from Taiwan facility planned for Q4 2025.
2. ElectroPulse PFA System (Investigational): The ElectroPulse PFA System is currently an investigational device not available for sale. It is undergoing multi-centre pivotal clinical trials as of late 2025. Future revenue expected upon regulatory approval.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

CathRx designs, develops, and manufactures modular electrophysiology (EP) catheters used by cardiac specialists to diagnose and treat cardiac arrhythmias, particularly atrial fibrillation. Its commercialized Khelix diagnostic catheter system offers loop, steerable, and fixed catheter variants configurable in over 300 ways. The investigational ElectroPulse pulsed-field ablation (PFA) system adds therapeutic ablation capability using 8F catheters and a 2800V generator for non-thermal tissue-selective ablation.

Product overview

CathRx offers two core product lines: the Khelix Diagnostic Electrophysiology Catheter system (commercially available) and the ElectroPulse Pulse Field Ablation (PFA) System (investigational). The Khelix system includes Fixed, Steerable, and Loop catheter variants designed for cardiac mapping and arrhythmia diagnosis, offering over 300 configuration options. The ElectroPulse PFA System is a therapeutic ablation platform consisting of 8F ablation catheters (Variable Loop, Linear Tip, and Big Eye Focal variants) with a 2800V generator, designed for both diagnostic and therapeutic functions in atrial fibrillation treatment. The Khelix diagnostic platform serves as the proven cost-effective foundation for the ElectroPulse PFA catheters, enabling shared manufacturing efficiency.

Differentiator

Problem solved

Functional benefit

Brands

• Khelix: Khelix is a diagnostic electrophysiology catheter brand offering loop, steerable, and fixed catheter configurations. The catheters are designed for precision and control in EP diagnostics and procedures.
• ElectroPulse

Products and services

• Khelix Diagnostic Electrophysiology Catheter System Modular diagnostic electrophysiology catheter system with more than 300 configuration options for cardiac mapping and arrhythmia diagnosis, available in three variants (Fixed, Steerable, and Loop) for electrophysiologists and hospitals performing EP procedures.
• Khelix Loop EP Catheter Loop electrophysiology catheter with a distal loop containing platinum-iridium electrodes for left atrium mapping, available in variable or fixed loop diameters (15-25mm) and equipped with a Loop Release safety mechanism for disentanglement.
• Khelix Steerable EP Catheter Unidirectional steerable electrophysiology catheter controlled by push/pull knob, available as single-use or reposable (up to 10 uses for certain variants) in various curve shapes and electrode configurations (4-20 electrodes).
• Khelix Fixed EP Catheter Fixed electrophysiology catheter with a catheter shaft containing platinum-iridium electrode array for stimulation and recording, available in multiple electrode configurations (4-6 electrodes) and curve types.
• ElectroPulse PFA System Pulsed Field Ablation (PFA) system for therapeutic treatment of atrial fibrillation, featuring 8F catheter designs, a 2800V generator, real-time tissue contact sensing, heartbeat synchronization, and dual-use diagnostic and therapeutic capability. Currently an investigational device undergoing pivotal clinical trials and not yet commercially available.

Quantifiable outcome

• 8F catheter size among the smallest on the market for reduced perforation risk
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

One partnership is on record.

• New DeantronicscoreTechnology or IntegrationNew Deantronics is CathRx's contract manufacturing partner located in Chiayi, Taiwan. They handle high-volume production of CathRx's catheter products, while CathRx's Rydalmere facility handles low-volume in-house production. Scale-up to the Taiwan facility is planned for Q4 2025 to support larger customer orders.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Boston Scientific: Boston Scientific acquired Farapulse, one of the leading commercialized pulsed field ablation (PFA) systems for atrial fibrillation. As a diversified cardiovascular medtech giant with deep EP infrastructure (including the Rhythmia mapping system), it competes directly with CathRx across both EP diagnostics and PFA therapy, and represents the gold standard commercial benchmark in the space.
• Johnson & Johnson (Biosense Webster): Biosense Webster, J&J's electrophysiology business, is the global EP market leader with the Carto 3D mapping system and Varipulse PFA catheter. It is the dominant incumbent CathRx competes against in cardiac EP labs worldwide, with unmatched sales coverage and clinical relationships.
• Medtronic: Medtronic's cardiac rhythm management franchise includes the PulseSelect PFA system (FDA-approved for AF) and the Affera mapping-and-ablation platform. As one of the four major incumbents in EP, it directly competes with CathRx's planned PFA offering and brings substantial clinical evidence and hospital relationships.
• Abbott: Abbott's electrophysiology portfolio includes the TactiFlex Ablation Catheter and the EnSite X 3D mapping system, with PFA development underway. It competes with CathRx across both EP diagnostics and ablation therapy, and is one of the four core incumbents shaping the PFA competitive landscape.

Direct peers

• Acutus Medical: Acutus Medical developed EP mapping catheters and ablation technologies for arrhythmia treatment, with a comparable niche-player profile to CathRx. Its AcQMap system and prior PFA efforts make it a directly comparable emerging EP player competing for similar hospital customers and PFA market entry.
• Galaxy Medical: Galaxy Medical develops pulsed electric field (PEF) ablation systems including the CENTAURI and ECLIPSE platforms, focusing on cardiac arrhythmia treatment. It is a direct emerging peer to CathRx in the PFA space, and notably Galaxy Medical's VP-level talent overlaps with CathRx's Head of Commercial.
• Biotronik: Biotronik manufactures electrophysiology catheters and cardiac rhythm management devices, including diagnostic and ablation catheters for arrhythmia treatment. It is a directly comparable EP-focused mid-sized player competing in similar hospital accounts and serving electrophysiologists globally.
• MicroPort Scientific: MicroPort's cardiac rhythm management business develops and commercializes electrophysiology catheters and ablation technologies, including PFA systems, in competition with global EP players. It is comparable to CathRx as a global EP/PFA catheter developer with similar customer base and product categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks2 records

Key highlights6 records

Customer concentration

• Xx.com/CathrxL
• LinkedInlinkedin.com/company/cathrx-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CathRx